Therapy of Relapsed Acute Myeloid Leukemia Using Targeted Plasma Concentrations of Cytosine Arabinoside and Etoposide

摘要: While the outcome for children with acute lymphocytic leukemia (ALL) has improved as a result of increased dose intensity, same improvement not occurred in myeloid (AML). Although approximately 85% AML achieve complete remission (CR), majority ultimately relapse and die their disease [1–5]. bone marrow transplant (BMT) offers better control, patient selection timing transplantation remains controversial [6–8]. Furthermore, because risk early death development graftversus-host disease, clinical trials have clearly demonstrated that BMT is treatment choice first CR [9].